Verastem, Inc. (VSTM) Stock Price & Analysis
Verastem, Inc. (VSTM) fell 2.10% to USD 6.05 as of July 25, 2026 at 06:09 UTC, according to Nexqual real-time market data.
VSTM last closed at USD 6.18; the session ranged USD 5.85–6.25 on volume of 2,531,668 shares. Market capitalization is $531.64M, with a 52-week range of USD 3.43–11.25 (NCM). Source: Nexqual, July 25, 2026 at 06:09 UTC.
Key Statistics (as of July 25, 2026 at 06:09 UTC)
| Price | USD 6.05 |
|---|---|
| Change | ▼ 2.10% (down) |
| Previous Close | USD 6.18 |
| Open | USD 6.2 |
| Day Range | USD 5.85 – 6.25 |
| 52-Week Range | USD 3.43 – 11.25 |
| Volume | 2,531,668 shares |
| Market Cap | $531.64M |
| Exchange | NCM |
Technical Analysis (VSTM)
Nexqual's technical model rates VSTM "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 06:09 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 69.94 (neutral) |
| vs SMA50 | Above (USD 4.53) |
| MACD | 0.48 (positive) |
Analyst Ratings (VSTM)
Wall Street analysts rate VSTM "Strong Buy" based on 8 analysts, with a mean price target of USD 15 (range USD 8–18), per Nexqual as of July 25, 2026 at 06:09 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 15 |
| High Target | USD 18 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (VSTM)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.45 |
| Revenue Estimate | $22.88M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.43 vs est -0.47 ▲ beat |
| 2025-12-31 | USD -0.46 vs est -0.5 ▲ beat |
| 2025-09-30 | USD -0.54 vs est -0.61 ▲ beat |
| 2025-06-30 | USD -0.63 vs est -0.75 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:09 UTC.
Financials & Fundamentals (VSTM)
| Total Revenue | $49.59M |
|---|---|
| Gross Margin | +85.13% |
| Operating Margin | -240.46% |
| Profit Margin | +0.00% |
| ROE | -786.15% |
| Debt / Equity | 104.52 |
| Current Ratio | 3.04 |
| Total Cash | $181.68M |
| Total Debt | $85.47M |
| Free Cash Flow | $-92.68M |
Source: Nexqual, July 25, 2026 at 06:09 UTC.
Financial Health Score (VSTM)
Nexqual rates Verastem, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:09 UTC.
| Growth | Strong — Revenue +209% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $182M cash vs $85M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$93M, burning cash |
| Efficiency | Critical — ROE -786%, ROA -59.4% |
Ownership (VSTM)
| Insider Ownership | +0.93% |
|---|---|
| Institutional Ownership | +98.33% |
| Shares Outstanding | 87.87M |
| Float | 70.38M |
| Short % of Float | +23.02% |
Source: Nexqual, July 25, 2026 at 06:09 UTC.
Leadership (VSTM)
Verastem, Inc. is led by Daniel W. Paterson (age 64), President, CEO & Director, per Nexqual as of July 25, 2026 at 06:09 UTC.
| President, CEO & Director | Daniel W. Paterson (age 64) |
|---|---|
| Chief Financial Officer | Daniel Calkins (age 37) |
| President of Development & Director | Michael Glen Kauffman (age 62) |
| Executive Vice President of Portfolio Strategy & Operations | Lori Horvat |
| Chief Scientific Officer | Jonathan Pachter (age 67) |
Major Backers & Investors (VSTM)
Notable institutional backers of Verastem, Inc. include RTW Investments LP, Deep Track Capital, Lp, Armistice Capital, LLC, according to Nexqual as of July 25, 2026 at 06:09 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 7.48% |
| Deep Track Capital, Lp | 6.53% |
| Armistice Capital, LLC | 5.23% |
| Nantahala Capital Management, LLC | 4.08% |
| Stonepine Capital Management, LLC | 3.76% |
| Foresite Capital Management VI LLC | 3.58% |
| Millennium Management | 2.74% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.17% |
| State Street | 7.84% |
| Vanguard Group | 7.82% |
Source: Nexqual, July 25, 2026 at 06:09 UTC.
From Verastem, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
- Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
- It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans.
- In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc. | USD 7.41 | ▲ 3.2% |
| VTVT | vTv Therapeutics Inc. | USD 30.73 | ▼ 2.97% |
| TLPH | Talphera, Inc. | USD 1.35 | ▲ 4.65% |
| RIGL | Rigel Pharmaceuticals, Inc. | USD 36.74 | ▼ 2.8% |
| VTGN | VistaGen Therapeutics, Inc. | USD 0.23 | ▼ 1.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:09 UTC. This page is informational and not investment advice.